Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment ...
June 03 2021 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, today announced it received a Notice of Allowance
from the United States Patent and Trademark Office (USPTO) for its
patent application number 16/166,732 expanding coverage of
treatment methods for ANAVEX®2-73 (blarcamesine), to the treatment
of a range of cardiac dysfunctions including cardiac arrhythmia,
ventricular arrhythmia and atrial fibrillation among other
indications.
Data suggests that activation of the sigma-1
receptor is pivotal to restoring neural cell homeostasis and
promoting neuroplasticity.1
Anavex’s newest patent is expected to remain in
force at least until 2038, not including any patent term
extensions. The new patent will expand the use of ANAVEX®2-73
(blarcamesine) from neurodegenerative and neurodevelopmental
disorders to a range of cardiac dysfunctions.
“This new use of ANAVEX®2-73 (blarcamesine) will
be exceptionally important for Alzheimer’s disease patients because
the advanced age of these patients make them also more susceptible
to heart disease,” said Christopher U. Missling, PhD, President and
Chief Executive Officer of Anavex, adding: “We are extremely
pleased with the continued development of the patent portfolio for
ANAVEX®2-73 (blarcamesine). When it issues, this new patent will
fortify our robust patent portfolio relating to ANAVEX®2-73
(blarcamesine), and further demonstrate our strong overall
commitment to protecting the innovation and commercial opportunity
of our product portfolio”.
About Cardiac Dysfunction
Heart disease is the leading cause of death for
men, women, and people of most racial and ethnic groups in the
United States. About 655,000 Americans die from heart disease each
year — that is 1 in every 4 deaths.2 Heart disease costs the U.S.
about $219 billion each year — this includes the cost of health
care services, medicines, and lost productivity due to death.3
Cardiac dysfunctions may be caused by and/or related to many other
heart diseases, such as coronary artery disease (CAD), high blood
pressure, a disorder of the heart muscle or heart valves, and heart
attack. It includes cardiac arrhythmia, premature ventricular
contraction (PVC), ventricular dysfunction, ventricular arrhythmia,
atrial fibrillation, and atrial flutter, among others.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, pain and various types of
cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine),
successfully completed a Phase 2a clinical trials for Alzheimer’s
disease and recently a Phase 2 proof-of-concept study in
Parkinson’s disease dementia and a Phase 2 study in adult patients
with Rett syndrome. ANAVEX®2-73 is an orally available drug
candidate that restores cellular homeostasis by targeting sigma-1
and muscarinic receptors. Preclinical studies demonstrated its
potential to halt and/or reverse the course of Alzheimer’s disease.
ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic,
neuroprotective, and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research previously awarded Anavex a research grant, which fully
funded a preclinical study to develop ANAVEX®2-73 for the treatment
of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and
muscarinic receptors, is a promising clinical stage drug candidate
demonstrating disease-modifying activity against the major
hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies. In
preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors:Andrew J.
BarwickiInvestor RelationsTel: 516-662-9461Email:
andrew@barwicki.com
1 Advances in Experimental Medicine and Biology
Volume 964 (2017) Sigma Receptors: Their Role in Disease and as
Therapeutic Targets.
2 Virani SS, Alonso A, Benjamin EJ, Bittencourt
MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke
Statistics—2020 Update: A Report From the American Heart
Association. Circulation. 2020;141(9):e139–e596.
3 CDC Centers for Disease Control and Prevention
- Heart Disease Facts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024